FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3121125508> ?p ?o ?g. }

• W3121125508 endingPage "S799" @default.
• W3121125508 startingPage "S799" @default.
• W3121125508 abstract "Abstract Background Relebactam (REL) inhibits class A and C β-lactamases and was approved in the US combined with imipenem (IMI) and cilastatin for complicated urinary tract and intraabdominal infections. Using isolates collected as part of the global SMART surveillance program in the US, we evaluated the activity of IMI/REL against gram-negative pathogens (GNP) from patients with lower respiratory tract infections (LRTI), including a comparison of isolates from ICU and non-ICU wards. Methods In 2017-2018, 27 US hospitals each collected up to 100 consecutive aerobic or facultative GNP from LRTI patients per year. MICs were determined using CLSI broth microdilution and breakpoints. Results Among 3878 GNP isolates from LRTI, the most common species collected were P. aeruginosa (Psa, 33.3%), K. pneumoniae (10.9%), E. coli (10.4%), and S. marcescens (6.9%). Susceptibility of GNP is shown in the table. IMI/REL inhibited 93% of Psa and Enterobacterales, which included 174 isolates of Morganellaceae that are not expected to be susceptible to IMI or IMI/REL. S. marcescens also showed low susceptibility to IMI, with improved but still reduced activity upon addition of REL. IMI/REL inhibited 83% of all GNP combined, 7-18 percentage points higher than the comparator β-lactams. Of the tested comparators, only amikacin exceeded the activity of IMI/REL. Only Psa showed substantial differences in susceptibility between isolates from ICU (n=486) and non-ICU wards (n=611), with 63.4% and 70.2%, respectively, susceptible to IMI, 71.6/78.7% to cefepime, and 64.2/73.3% to piperacillin/tazobactam (P/T). Susceptibility to IMI/REL was high in both settings (91.4/93.6%). Among Enterobacterales, susceptibility was generally similar in ICU and non-ICU wards (IMI/REL, 92.5% in both settings; IMI, 86.3 and 87.1%, respectively; cefepime, 89.9/89.0%; P/T, 88.7/87.4%). Table Conclusion Although resistance rates have frequently been reported to be higher in ICU than non-ICU wards, this pattern was seen in the current study only among Psa isolates. IMI/REL showed activity &gt;90% against both Enterobacterales and Psa from both ward types. These in vitro data suggest that IMI/REL could provide an important treatment option for patients with LRTI in the US, including those in ICUs. Disclosures Sibylle Lob, PhD, IHMA (Employee)Pfizer, Inc. (Consultant) Katherine Young, MS, Merck & Co., Inc. (Employee, Shareholder)Merck & Co., Inc. (Employee, Shareholder) Mary Motyl, PhD, Merck & Co, Inc (Employee, Shareholder) Daniel F. Sahm, PhD, IHMA (Employee)Pfizer, Inc. (Consultant)Shionogi & Co., Ltd. (Independent Contractor)" @default.
• W3121125508 created "2021-01-18" @default.
• W3121125508 creator A5017159626 @default.
• W3121125508 creator A5038009031 @default.
• W3121125508 creator A5042149117 @default.
• W3121125508 creator A5062847775 @default.
• W3121125508 creator A5089366807 @default.
• W3121125508 date "2020-10-01" @default.
• W3121125508 modified "2023-10-18" @default.
• W3121125508 title "1609. Epidemiology and Susceptibility to Imipenem/Relebactam of Gram-Negative Pathogens from Patients with Lower Respiratory Tract Infections – SMART United States 2017-2018" @default.
• W3121125508 doi "https://doi.org/10.1093/ofid/ofaa439.1789" @default.
• W3121125508 hasPublicationYear "2020" @default.
• W3121125508 type Work @default.
• W3121125508 sameAs 3121125508 @default.
• W3121125508 citedByCount "0" @default.
• W3121125508 crossrefType "journal-article" @default.
• W3121125508 hasAuthorship W3121125508A5017159626 @default.
• W3121125508 hasAuthorship W3121125508A5038009031 @default.
• W3121125508 hasAuthorship W3121125508A5042149117 @default.
• W3121125508 hasAuthorship W3121125508A5062847775 @default.
• W3121125508 hasAuthorship W3121125508A5089366807 @default.
• W3121125508 hasBestOaLocation W31211255081 @default.
• W3121125508 hasConcept C126322002 @default.
• W3121125508 hasConcept C176947019 @default.
• W3121125508 hasConcept C2776012195 @default.
• W3121125508 hasConcept C2776685102 @default.
• W3121125508 hasConcept C2777050379 @default.
• W3121125508 hasConcept C2777427914 @default.
• W3121125508 hasConcept C2779375183 @default.
• W3121125508 hasConcept C2779631663 @default.
• W3121125508 hasConcept C2780950330 @default.
• W3121125508 hasConcept C501593827 @default.
• W3121125508 hasConcept C534529494 @default.
• W3121125508 hasConcept C71924100 @default.
• W3121125508 hasConcept C86803240 @default.
• W3121125508 hasConcept C89423630 @default.
• W3121125508 hasConcept C94665300 @default.
• W3121125508 hasConceptScore W3121125508C126322002 @default.
• W3121125508 hasConceptScore W3121125508C176947019 @default.
• W3121125508 hasConceptScore W3121125508C2776012195 @default.
• W3121125508 hasConceptScore W3121125508C2776685102 @default.
• W3121125508 hasConceptScore W3121125508C2777050379 @default.
• W3121125508 hasConceptScore W3121125508C2777427914 @default.
• W3121125508 hasConceptScore W3121125508C2779375183 @default.
• W3121125508 hasConceptScore W3121125508C2779631663 @default.
• W3121125508 hasConceptScore W3121125508C2780950330 @default.
• W3121125508 hasConceptScore W3121125508C501593827 @default.
• W3121125508 hasConceptScore W3121125508C534529494 @default.
• W3121125508 hasConceptScore W3121125508C71924100 @default.
• W3121125508 hasConceptScore W3121125508C86803240 @default.
• W3121125508 hasConceptScore W3121125508C89423630 @default.
• W3121125508 hasConceptScore W3121125508C94665300 @default.
• W3121125508 hasIssue "Supplement_1" @default.
• W3121125508 hasLocation W31211255081 @default.
• W3121125508 hasLocation W31211255082 @default.
• W3121125508 hasLocation W31211255083 @default.
• W3121125508 hasOpenAccess W3121125508 @default.
• W3121125508 hasPrimaryLocation W31211255081 @default.
• W3121125508 hasRelatedWork W13584953 @default.
• W3121125508 hasRelatedWork W14870853 @default.
• W3121125508 hasRelatedWork W15114432 @default.
• W3121125508 hasRelatedWork W15618799 @default.
• W3121125508 hasRelatedWork W175918 @default.
• W3121125508 hasRelatedWork W20601958 @default.
• W3121125508 hasRelatedWork W2478729 @default.
• W3121125508 hasRelatedWork W5251251 @default.
• W3121125508 hasRelatedWork W7805384 @default.
• W3121125508 hasRelatedWork W9389675 @default.
• W3121125508 hasVolume "7" @default.
• W3121125508 isParatext "false" @default.
• W3121125508 isRetracted "false" @default.
• W3121125508 magId "3121125508" @default.
• W3121125508 workType "article" @default.